Year: 2012
Type: article
Abstract: Candida auris is an emerging fungal pathogen that exhibits resistance to multiple drugs, including the most commonly prescribed antifungal, fluconazole. Here, we use a combinatorial screening approach to identify a bis-benzodioxolylindolinone (azoffluxin) that synergizes with fluconazole against C. auris. Azoffluxin enhances fluconazole activity through the inhibition of efflux pump Cdr1, thus increasing intracellular fluconazole levels. This activity is conserved across most C. auris clades, with the exception of clade III. Azoffluxin also inhibits efflux in highly azole-resistant strains of Candida albicans, another human fungal pathogen, increasing their susceptibility to fluconazole. Furthermore, azoffluxin enhances fluconazole activity in mice infected with C. auris, reducing fungal burden. Our findings suggest that pharmacologically targeting Cdr1 in combination with azoles may be an effective strategy to control infection caused by azole-resistant isolates of C. auris.
Source: BIO-PROTOCOL
Authors: Jinglin Xie, Sheena Singh-Babak, Leah Cowen
Institution: University of Toronto
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Advancing genomic, transcriptomic and functional approaches to combat globally important and emerging pathogens, Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens, G357492381, Myosin I in epithelial cell-cell contact and polarity, BU-CMD Chemical Library Consortium: Fostering Collaborations between Chemists and Biologists for Translational Discovery, G6744227308, G8310580569, Vesicle-mediated drug resistance of Candida albicans biofilm, Chemical Synthesis of Complex Natural Products for Translational Science
OpenAlex ID: W2525765531
